This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xie, X. Articles by Spencer, D. M. Search for Related Content PubMed PubMed Citation Articles by Xie, X. Articles by Spencer, D. M.

Adenovirus-mediated Tissue-targeted Expression of a Caspase-9-based Artificial Death Switch for the Treatment of Prostate Cancer¹

Departments of Immunology [X. X., X. Z., Y. L., D. M. S.] and Urology [K. M. S.], Baylor College of Medicine, Houston, Texas 77030, and Department of Urologic Surgery, Vanderbilt Prostate Cancer Center, Nashville, Tennessee 37232 [J. Z., R. J. M.]

Clinical experience with suicide gene therapy for prostate cancer using first-generation approaches has provided a basis for developing improved strategies. Given the low proliferation rate exhibited by prostate cancer, one improvement would be to develop suicide genes that effectively kill both dividing and nondividing cells. A second improvement would be to restrict cytotoxicity to prostate cancer cells, limiting injury of nondiseased tissue. Here we describe a novel approach to achieving both goals based on: (a) the use of a small, but potent, prostate-specific composite promoter, ARR₂PB, based on the rat probasin gene; and (b) the use of a powerful artificial death switch, called inducible caspase-9 (iCaspase-9). ARR₂PB includes two copies of the androgen response region (ARR), each containing two androgen receptor (AR)-binding sites, placed upstream of the probasin promoter elements necessary for basal transcription. Because iCaspase-9 contains two binding sites for the dimeric ligand, AP20187, administration of chemical inducers of dimerization leads to aggregation and caspase activation, followed by rapid apoptosis in both dividing and nondividing cells. Using both reagents, we constructed two novel adenoviruses (ADVs), ADV.ARR₂PB-iCasp9 expressing iCaspase-9 and control ADV.ARR₂PB-EGFP expressing enhanced green fluorescent protein (EGFP). We demonstrate that tissue specificity is not sacrificed in an ADV backbone because the marker protein, EGFP, is expressed in R1881-stimulated ADV.ARR₂PB-EGFP-transduced LNCaP cells but not in AR^- PC-3, 293, HuH-7, U-87, and MCF-7 cells. Similarly, Pro-iCaspase-9 is expressed in ADV.ARR₂PB-iCasp9-infected LNCaP cells after R1881 administration and is activated after AP20187 administration. In vitro experiments revealed rapid and efficient iCaspase-9-induced apoptosis of LNCaP cells in both an R1881- and AP20187-dependent manner. Only 28, 8, and 0.5% survival of LNCaP cells was seen at multiplicities of infection of 2, 10, and 25, respectively. Furthermore, at a multiplicity of infection of 10, extraordinary sensitivity to AP20187 was seen (IC₅₀, 3 pM). In vivo experiments showed that ADV.ARR₂PB-iCasp9 induced apoptosis in LNCaP but not in HuH-7 xenograft tumors in an AP20187-dependent manner. Furthermore, a simple i.p. injection of AP20187 dramatically suppressed LNCaP tumor growth in nude mice and led to a significantly increased host survival. This study demonstrates the feasibility of using tissue-specific expression of cell cycle-independent iCaspases as a nonmutagenic alternative modality for prostate cancer suicide gene therapy.

This article has been cited by other articles:

				Y. Xie, K. Xu, D. E. Linn, X. Yang, Z. Guo, H. Shimelis, T. Nakanishi, D. D. Ross, H. Chen, L. Fazli, et al. The 44-kDa Pim-1 Kinase Phosphorylates BCRP/ABCG2 and Thereby Promotes Its Multimerization and Drug-resistant Activity in Human Prostate Cancer Cells J. Biol. Chem., February 8, 2008; 283(6): 3349 - 3356. [Abstract] [Full Text] [PDF]

				H. Zeng, Q. Wei, R. Huang, N. Chen, Q. Dong, Y. Yang, and Q. Zhou Recombinant Adenovirus Mediated Prostate-Specific Enzyme Pro-Drug Gene Therapy Regulated by Prostate-Specific Membrane Antigen (PSMA) Enhancer/Promoter J Androl, November 1, 2007; 28(6): 827 - 835. [Abstract] [Full Text] [PDF]

				M. R. Seethammagari, X. Xie, N. M. Greenberg, and D. M. Spencer EZC-Prostate Models Offer High Sensitivity and Specificity for Noninvasive Imaging of Prostate Cancer Progression and Androgen Receptor Action. Cancer Res., June 15, 2006; 66(12): 6199 - 6209. [Abstract] [Full Text] [PDF]

				M. S. Ricci and W.-X. Zong Chemotherapeutic approaches for targeting cell death pathways. Oncologist, April 1, 2006; 11(4): 342 - 357. [Abstract] [Full Text] [PDF]

				U. Fischer and K. Schulze-Osthoff New Approaches and Therapeutics Targeting Apoptosis in Disease Pharmacol. Rev., June 1, 2005; 57(2): 187 - 215. [Abstract] [Full Text] [PDF]

				E. Yu. Nikitina, S. A. Desai, X. Zhao, W. Song, A. Z. Luo, R. D. Gangula, K. M. Slawin, and D. M. Spencer Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12 Cancer Res., May 15, 2005; 65(10): 4309 - 4319. [Abstract] [Full Text] [PDF]

				X. Liao, J. B. Thrasher, J. Holzbeierlein, S. Stanley, and B. Li Glycogen Synthase Kinase-3{beta} Activity Is Required for Androgen-Stimulated Gene Expression in Prostate Cancer Endocrinology, June 1, 2004; 145(6): 2941 - 2949. [Abstract] [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]

				W.-S. Cheng, V. Giandomenico, I. Pastan, and M. Essand Characterization of the Androgen-Regulated Prostate-Specific T Cell Receptor {gamma}-Chain Alternate Reading Frame Protein (TARP) Promoter Endocrinology, August 1, 2003; 144(8): 3433 - 3440. [Abstract] [Full Text] [PDF]

				C. R. Logg, A. Logg, R. J. Matusik, B. H. Bochner, and N. Kasahara Tissue-Specific Transcriptional Targeting of a Replication-Competent Retroviral Vector J. Virol., December 15, 2002; 76(24): 12783 - 12791. [Abstract] [Full Text] [PDF]

				P. S. Schwartz, C.-S. Chen, and D. J. Waxman Enhanced Bystander Cytotoxicity of P450 Gene-directed Enzyme Prodrug Therapy by Expression of the Antiapoptotic Factor p35 Cancer Res., December 1, 2002; 62(23): 6928 - 6937. [Abstract] [Full Text] [PDF]